Low-level expression of human Epidermal growth Factor Receptor-2 (HER2) in High-Grade Mullerian Tumors: Implications for therapy decision making
Introduction: Reclassification of HER2-negative breast cancers to HER2 low-level expression allowed targeted anti-HER2 therapy in about 60% of patients, improving outcome. The high recurrence rates and often dismal outcomes with current therapies of high-grade Mullerian carcinomas, offers opportunit...
Saved in:
Main Authors: | Evi Abada (Author), Kamaljeet Singh (Author), Katrine Hansen (Author), M. Ruhul Quddus (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: Report of scenarios of unusual overexpression
by: M. Ruhul Quddus, et al.
Published: (2020) -
Variants of in situ carcinoma of the endometrium: Clear cell and gastrointestinal types, with a review of the literature
by: Evi Abada, et al.
Published: (2022) -
Cell Internalization in Fluidic Culture Conditions Is Improved When Microparticles Are Specifically Targeted to the Human Epidermal Growth Factor Receptor 2 (HER2)
by: Inmaculada Mora-Espí, et al.
Published: (2019) -
Screening of potential phytocompounds from Euclea crispa (Thunb.) leaves targeting human epidermal growth factor receptor 2 (HER2) signaling pathway
by: Chella Perumal Palanisamy, et al.
Published: (2019) -
Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens
by: Furrer Daniela, et al.
Published: (2013)